Find information on thousands of medical conditions and prescription drugs.

Essential thrombocythemia

Essential thrombocytosis (ET, essential thrombocythemia) is a rare and chronic blood disorder characterized by the overproduction of megakaryocytes (the precursor cell for platelets). Most of these patients will have platelet counts over 600,000 per cubic mm. In some cases this disorder may be progressive, and (very rarely) evolves into acute leukemia or myelofibrosis. more...

Home
Diseases
A
B
C
D
E
Ebola hemorrhagic fever
Ebstein's anomaly
Eclampsia
Ectodermal Dysplasia
Ectopic pregnancy
Ectrodactyly
Edwards syndrome
Ehlers-Danlos syndrome
Ehrlichiosis
Eisoptrophobia
Elective mutism
Electrophobia
Elephantiasis
Ellis-Van Creveld syndrome
Emetophobia
Emphysema
Encephalitis
Encephalitis lethargica
Encephalocele
Encephalomyelitis
Encephalomyelitis, Myalgic
Endocarditis
Endocarditis, infective
Endometriosis
Endomyocardial fibrosis
Enetophobia
Enterobiasis
Eosinophilia-myalgia...
Eosinophilic fasciitis
Eosophobia
Ependymoma
Epicondylitis
Epidermolysis bullosa
Epidermolytic hyperkeratosis
Epididymitis
Epilepsy
Epiphyseal stippling...
Epistaxiophobia
EPP (erythropoietic...
Epstein barr virus...
Equinophobia
Ergophobia
Erysipelas
Erythema multiforme
Erythermalgia
Erythroblastopenia
Erythromelalgia
Erythroplakia
Erythropoietic...
Esophageal atresia
Esophageal varices
Esotropia
Essential hypertension
Essential thrombocythemia
Essential thrombocytopenia
Essential thrombocytosis
Euphobia
Evan's syndrome
Ewing's Sarcoma
Exencephaly
Exophthalmos
Exostoses
Exploding head syndrome
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Pathophysiology

The pathologic basis for this disease is unknown. However, essential thrombosis resembles polycythemia vera in that cells of the megakaryocytic series are more sensitive to growth factors. Platelets derived from the abnormal megakaryocytes do not function properly, which contributes to the clinical features of bleeding and thrombosis.

Recently, in 2005, a mutation in the JAK2 kinase (V617F) was found by multiple research groups (Baxter et al., 2005; Levine et al., 2005) to be associated with essential thrombocytosis. JAK2 is a member of the Janus kinase family. This mutation be helpful in making a diagnosis or as a target for future therapy.

Clinical findings and symptoms

Essential thrombocytosis is the most rare of the myeloproliferative family of diseases. The major symptoms are bleeding and thrombosis. Other symptoms include an enlarged spleen (splenomegaly), epistaxis (nosebleeds) and bleeding from gums and gastrointestinal tract. One characteristic symptom is throbbing and burning of the hands and feet due to the occlusion of small arterioles by platelets (erythromelalgia).

Clinical course

Essential thrombocytosis is a slowly progressing disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic crises. It is diagnosed at a rate of about 2 to 3 per 100,000 individuals and usually affects middle aged to elderly individuals (although it can affect children and young adults). The median survival time for patients with this disorder is 12 to 15 years.

Treatment

In cases where patients have life-threatening complications, the platelet count can be reduced rapidly through platelet apheresis (a procedure that removes platelets from the blood directly). Long-term decreases in platelet counts can reduce bleeding and clotting complications. Common medications include hydroxyurea, interferon-alpha, or anagrelide. Aspirin may also help decrease clotting.

Read more at Wikipedia.org


[List your site here Free!]


Essential thrombocythemia associated with angina pectoris with unusual coronary artery findings
From CHEST, 10/1/91 by Hiroshi Yoshida

A case of ET associated with angina pectoris is presented. Angiography showed a 3.0-cm long mosaic-like thrombus shadow consisting of small filling defects in the proximal left anterior descending artery. The lesion could not be reduced with warfarin, ticlopidine, trapidil, urokinase or melphalan. Coronary artery bypass grafting was performed successfully.

ET = essential thrombocythemia; IMA = internal mammary artery; RAO = right anterior oblique; LAO = left anterior oblique; PTCA = percutaneous transluminal coronary angiography

Essential thrombocythemia, a myeloproliferative disorder, may result in thrombus formation and acute vascular occlusion. However, coronary artery occlusion in patients with ET rarely has been described. The effect of chemotherapy suppressing bone marrow activity is controversial. We describe a patient with ET who had unusual coronary arteriographic features and who underwent CABG successfully while being treated with melphalan.

Case Report

A 52-year-old man visited our hospital because of angina pectoris and thrombocythemia. He was well until seven months earlier, when chest pain on effort appeared. He was admitted to another hospital. Coronary arteriography showed a 3.0-cm long mosaic-like thrombus shadow consisting of small filling defects in the proximal left anterior descending artery associated with delayed filling of the distal coronary artery. The first diagonal branch was totally occluded and filled poorly by collaterals from the circumflex artery. The other vessels were entirely normal. The platelet count was 1,092,000/cu mm and the remainder of the hemogram was normal. Ticlopidine, 100 mg twice daily; trapidil, 100 mg three times daily; and diltiazem, 30 mg three times daily, were started. After three months of medication, coronary arteriography was repeated. Urokinase, in a dose of 240,000 units, was infused into the left coronary artery, but the lesion did not change. Thallium 201 exercise scintigraphy revealed reversible perfusion of the anteroseptal wall of the left ventricle. He was referred to our hospital. Bone marrow examination revealed increased megakaryocytes and a mildly hypercellular marrow, confirming the diagnosis of ET. The aggregation of platelets with epinephrine, adenosine diphosphate and collagen was normal. Bleeding time, coagulation time, prothrombin time, partial thromboplastin time and thromboelastogram also were normal. Diltiazem, 30 mg three times daily, long-acting isosorbide dinitrate, 20 mg three times daily; metoprolol, 20 mg twice daily; warfarin sulfate, 3 mg daily; and melphalan, 2 mg daily, were administered. Three months after the start of melphalan treatment, the platelet count was 400,000/cu mm and a third cardiac catheterization was performed. Coronary arteriography revealed total occlusion of the left anterior descending artery with good filling by collaterals from the right coronary artery, and the recanalized first diagonal branch contained small filling defects similar to the lesions previously seen in the left anterior descending artery. Left ventriculography showed normal contractions. Transient ischemia, coincident with anginal pain, was noted in the anteroseptal wall on thallium 201 stress scintigraphy, similar to that seen in the previous thallium 201 stress scintigraphy. We performed CABG using the left IMA. There were no thrombohemorrhagic complications. He has been free from anginal pain since surgery.

Discussion

Essential thrombocythemia is a myeloproliferative disorder characterized by isolated overproduction of platelets and an increased risk of thrombohemorrhagic complications.[1] The most common symptom of ET is excessive bleeding; thromboembolism is less fequent. One of the potentially fatal but rare thromboembolic complications is ischemic heart disease. Decreased platelet aggregation, particularly with adenosine diphosphate and epinephrine, is often observed. The aim of therapy for ET is suppression of the excessive bone marrow activity, which can be achieved by whole-body irradiation or chemotherapy with small doses of busulfan or melphalan. However, a direct relationship between platelet count or mass and risk of complications has not been conclusively demonstrated, and no randomized prospective data exist to prove that routine suppression of the platelet count prolongs survival or reduces the incidence of symptoms.[2] So the indications for treatment of ET are controversial. However ET associated with potentially fatal complications should be treated as soon as the diagnosis is made.

Reports of ET associated with ischemic heart disease have been made, and there are two types of coronary arteriographic findings. In one, there are normal coronary arteries without atherosclerosis[3,4] and in the other, there is coronary artery stenosis in young men.[5,6] In the former type, thrombus formation could cause myocardial infarction, so chemotherapy and treatment with an antiplatelet agent might be effective in preventing an ischemic event.[3,4] In the latter type, significant stenosis often is located in the left anterior descending artery Medical therapy alone cannot reduce the stenosis, and interventional treatment is needed. Pick et al[5] described a patient with a stenotic lesion treated with CABG because of the length of his lesion and the high platelet count with its proclivity toward excessive bleeding and thrombosis. Hanger et al[6] performed PTCA successfully in a patient being treated with busulfan, aspirin and diltiazem. There is no reason for ET to affect the left anterior descending artery most often. In our patient, the coronary artery lesion had more complex morphology and was obviously different from that of previously reported cases. In ours, a 3.0-cm long mosaic-like thrombus shadow made up of small filling defects was observed in the proximal left anterior descending artery. There had been no improvement with urokinase, ticlopidine, trapidil, warfarin sulfate and melphalan treatment, although the platelet count had decreased. The lesion was thought to be neither a so-called thrombus formed at the time of infarction of a related artery nor the atherosclerosis usually observed in ischemic coronary artery disease, but perhaps a collection of small thrombi consisting of a random aggregation of platelet clumps. In this patient, PTCA was not indicated because of the complex long lesion with thrombi. Since the platelet count and platelet aggregation were well controlled, CABG was performed safely

References

[1] Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology, 4th ed. New York: McGraw Hill, 1990:232-36 [2] Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, et al. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33:27-31 [3] Douste-Blazy PH, Taudou MJ, Delay M, Pris J, Sie P, Ribaut L, et al. Essential thrombocythemia and recurrent myocardial infarction. Lancet 1984; 2:992 [4] Louwernburg JW, Suttorp MJ, Kingma JH. Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction. Am J Med 1987; 83:1175 [5] Pick RA, Glover MU, Nanfro JJ, Dubbs WF, Gibbsons JA, Vieweg WV. Acute myocardial infarction with essential thrombocythemia in a young man. Am Heart J 1983; 106:406-07 [6] Hanger KH Jr, Kilgore J, James E. Essential thrombocythemia and coronary artery disease. Chest 1984; 86:933-35

COPYRIGHT 1991 American College of Chest Physicians
COPYRIGHT 2004 Gale Group

Return to Essential thrombocythemia
Home Contact Resources Exchange Links ebay